Bm-32 * Ceritinib (Ldk378) for Treatment of Patients With Alk-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases (Bm) in the Ascend-1 Trial

Shaw, Alice T.; Mehra, Ranee; Tan, Daniel Shao-Weng; Felip, Enriqueta; Chow, Laura Q.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; Pas, Tommaso De; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schüler, Martin; Liu, Geoffrey; Santoro, Armando; Geraldes, Margarida; Sen, Paramita; Boral, Anthony J.; Yovine, Alejandro; Kim, Dong-Wan

doi:10.1093/neuonc/nou240.32

Cited by 20 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 28 ascend-1 patients with measurable brain metastases at baseline, 10 (36%) experienced a partial response 24 . As a result of the trial, the Food and Drug Administration approved ceritinib in April 2014 for patients with advanced ALK-positive nsclc after treatment with crizotinib.…”

Section: Ascend-1 -2 and -3mentioning

confidence: 99%

Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer

Melosky¹,

Agulnik

Albadine

et al. 2016

Current Oncology

Self Cite

View full text Add to dashboard Cite

Anaplastic lymphoma kinase (alk) is an oncogenic driver in non-small-cell lung cancer (nsclc). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis.Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population.Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation alk inhibitors can be considered.

show abstract

Section: Ascend-1 -2 and -3mentioning

confidence: 99%

Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer

Melosky¹,

Agulnik

Albadine

et al. 2016

Current Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In seven of them (four patients after previous therapy with ALK inhibitors and three without previous therapy) was detected PR and in three patients discovered SD (all after previous crizotinib therapy). The PFS was 6.9 months (range 5.4-8.4 months) for all patients or 6.7 months (range 4.9-8.4 months) for patients previously treated with ALK inhibitors and 8.3 months (range 4.6-not applicable) for patients who have not previously received ALK inhibitors [36] .…”

Section: Type Of Palliative Treatment Indicationsmentioning

confidence: 93%

Management of Brain Metastases from Solid Tumors

Любота¹,

Верещако²,

Anikusko³

et al. 2018

Cancer Management and Therapy

View full text Add to dashboard Cite

Brain metastases (BM) are most common intracranial tumors in adults. Recently, significant progress has been shown in diagnosing, prognosis, and treating patients with BM of various malignant tumors. The treatment decisions must be based on the disease prognosis and include radiation therapy, surgery, systemic antitumor therapy, or a combination thereof. Systemic therapy capable of preventing BM or which affects both intracranial and extracranial disease is of paramount importance in the treatment of BM patients. The purpose of this chapter is to consider important prognostic factors that can determine treatment decisions, review the role of blood-brain barrier (BBB), and systemic anticancer treatment to manage BM from solid tumors.

show abstract

“…The PFS was 6.9 months for all trial participants (28). Of the 28 subjects with measurable brain metastases at baseline, 35% ( n = 10) had a partial response (29). As a result of this trial, the FDA approved ceritinib for patients with advanced ALK -positive NSCLC following treatment with crizotinib in April 2014.…”

Section: Alk Mutation Positive Ncslcmentioning

confidence: 99%

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

Melosky

2017

Front. Oncol.

View full text Add to dashboard Cite

The treatment paradigm for metastatic non-small cell, non-squamous lung cancer is continuously evolving due to new treatment options and our increasing knowledge of molecular signal pathways. As a result of treatments becoming more efficacious and more personalized, survival for selected groups of non-small cell lung cancer (NSCLC) patients is increasing. In this paper, three algorithms will be presented for treating patients with metastatic non-squamous, NSCLC. These include treatment algorithms for NSCLC patients whose tumors have EGFR mutations, ALK rearrangements, or wild-type/wild-type tumors. As the world of immunotherapy continues to evolve quickly, a future algorithm will also be presented.

show abstract

Bm-32 * Ceritinib (Ldk378) for Treatment of Patients With Alk-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases (Bm) in the Ascend-1 Trial

Cited by 20 publications

References 0 publications

Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer

Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer

Management of Brain Metastases from Solid Tumors

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

Contact Info

Product

Resources

About